116 related articles for article (PubMed ID: 37544636)
1. Anlotinib exerts an anti-T-cell acute lymphoblastic leukemia effect in vitro and in vivo.
Zhang X; Geng L; Yang L; Wang Y; Zou Z; Zhang Y; Xu H; Lei H; Cao Y; Wu Y; Gu W; Zhou L
Cell Signal; 2023 Oct; 110():110837. PubMed ID: 37544636
[TBL] [Abstract][Full Text] [Related]
2. Autophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2/STAT3/VEGFA signaling in non-small cell lung cancer cells.
Liang L; Hui K; Hu C; Wen Y; Yang S; Zhu P; Wang L; Xia Y; Qiao Y; Sun W; Fei J; Chen T; Zhao F; Yang B; Jiang X
J Exp Clin Cancer Res; 2019 Feb; 38(1):71. PubMed ID: 30755242
[TBL] [Abstract][Full Text] [Related]
3. Stabilization of Notch1 by the Hsp90 Chaperone Is Crucial for T-Cell Leukemogenesis.
Wang Z; Hu Y; Xiao D; Wang J; Liu C; Xu Y; Shi X; Jiang P; Huang L; Li P; Liu H; Qing G
Clin Cancer Res; 2017 Jul; 23(14):3834-3846. PubMed ID: 28143869
[No Abstract] [Full Text] [Related]
4. Directly targeting c-Myc contributes to the anti-multiple myeloma effect of anlotinib.
Cao Y; Shan H; Liu M; Liu J; Zhang Z; Xu X; Liu Y; Xu H; Lei H; Yu M; Zhang X; Liu W; Bu Z; Fang Z; Ji Y; Yan H; Gu W; Wu Y
Cell Death Dis; 2021 Apr; 12(4):396. PubMed ID: 33854043
[TBL] [Abstract][Full Text] [Related]
5. Reactive oxygen species mediate anlotinib-induced apoptosis via activation of endoplasmic reticulum stress in pancreatic cancer.
Yang L; Zhou X; Sun J; Lei Q; Wang Q; Pan D; Ding M; Ding Y
Cell Death Dis; 2020 Sep; 11(9):766. PubMed ID: 32943607
[TBL] [Abstract][Full Text] [Related]
6. Anlotinib exerts anti-cancer efficiency on lung cancer stem cells in vitro and in vivo through reducing NF-κB activity.
Li Z; Tian J; Du L; Gao Y; Wang Y; You F; Wang L
J Cell Mol Med; 2021 Jun; 25(12):5547-5559. PubMed ID: 33955683
[TBL] [Abstract][Full Text] [Related]
7. Anlotinib Inhibits Ovarian Cancer and Enhances Cisplatinum Sensitivity
Xu X; Wang Q; Shen L; Shen Y; Liu H; Liu Y; Yang Z; Hoffman RM; Feng W
Anticancer Res; 2024 Apr; 44(4):1399-1407. PubMed ID: 38538004
[TBL] [Abstract][Full Text] [Related]
8. Flavone inhibited proliferation of T-ALL by promoting c-Cbl-induced ubiquitinylation and degradation of Notch1.
Zhu W; Zhu Y; Xu H; Wang T; Wang J; Meng M; Liu Y; Yan H; Yang Q; Liu P
Biochem Biophys Res Commun; 2020 Feb; 522(3):684-689. PubMed ID: 31785807
[TBL] [Abstract][Full Text] [Related]
9. Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma.
Song F; Hu B; Cheng JW; Sun YF; Zhou KQ; Wang PX; Guo W; Zhou J; Fan J; Chen Z; Yang XR
Cell Death Dis; 2020 Jul; 11(7):573. PubMed ID: 32709873
[TBL] [Abstract][Full Text] [Related]
10. Combination of anlotinib and gemcitabine promotes the G0/G1 cell cycle arrest and apoptosis of intrahepatic cholangiocarcinoma in vitro.
Fan S; Ge Y; Liu J; Liu H; Yan R; Gao T; Fan X; Xiao Z; An G
J Clin Lab Anal; 2021 Oct; 35(10):e23986. PubMed ID: 34462984
[TBL] [Abstract][Full Text] [Related]
11. Synergistic Antitumor Effects of Anlotinib Combined with Oral 5-Fluorouracil/S-1 via Inhibiting Src/AKT Signaling Pathway in Small-Cell Lung Cancer.
Xia X; Pi W; Lan Y; Wu X; Lv D; Meng Y; Yang H; Wang W
Anal Cell Pathol (Amst); 2022; 2022():4484211. PubMed ID: 35757014
[TBL] [Abstract][Full Text] [Related]
12. Anlotinib Inhibits Proliferation and Induces Apoptosis in B-cell Acute Lymphoblastic Leukemia by Targeting the BTK and AKT/mTOR Pathway.
Shi X; Li S; Tang S; Lu Y
Anticancer Agents Med Chem; 2023; 23(12):1397-1405. PubMed ID: 36856175
[TBL] [Abstract][Full Text] [Related]
13. Antitumor effects of anlotinib in thyroid cancer.
Ruan X; Shi X; Dong Q; Yu Y; Hou X; Song X; Wei X; Chen L; Gao M
Endocr Relat Cancer; 2019 Jan; 26(1):153-164. PubMed ID: 30139768
[TBL] [Abstract][Full Text] [Related]
14. Radiotherapy opens the blood-brain barrier and synergizes with anlotinib in treating glioblastoma.
Li PJ; Lai SZ; Jin T; Ying HJ; Chen YM; Zhang P; Hang QQ; Deng H; Wang L; Feng JG; Chen XZ; Guo P; Chen M; Tian Y; Chen YY
Radiother Oncol; 2023 Jun; 183():109633. PubMed ID: 36963438
[TBL] [Abstract][Full Text] [Related]
15. Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma.
Wang G; Sun M; Jiang Y; Zhang T; Sun W; Wang H; Yin F; Wang Z; Sang W; Xu J; Mao M; Zuo D; Zhou Z; Wang C; Fu Z; Wang Z; Duan Z; Hua Y; Cai Z
Int J Cancer; 2019 Aug; 145(4):979-993. PubMed ID: 30719715
[TBL] [Abstract][Full Text] [Related]
16. Anlotinib Inhibits Cell Proliferation, Migration and Invasion via Suppression of c-Met Pathway and Activation of ERK1/2 Pathway in H446 Cells.
Tang X; Zheng Y; Jiao D; Chen J; Liu X; Xiong S; Chen Q
Anticancer Agents Med Chem; 2021; 21(6):747-755. PubMed ID: 32682383
[TBL] [Abstract][Full Text] [Related]
17. Anti-cancer Drug Anlotinib Promotes Autophagy and Apoptosis in Breast Cancer.
Chen S; Gao Y; Zhu P; Wang X; Zeng L; Jin Y; Zhi X; Yang H; Zhou P
Front Biosci (Landmark Ed); 2022 Apr; 27(4):125. PubMed ID: 35468684
[TBL] [Abstract][Full Text] [Related]
18. Apatinib exhibits anti-leukemia activity in preclinical models of acute lymphoblastic leukemia.
Deng M; Zha J; Jiang Z; Jia X; Shi Y; Li P; Chen XL; Fang Z; Du Z; Xu B
J Transl Med; 2018 Feb; 16(1):47. PubMed ID: 29490645
[TBL] [Abstract][Full Text] [Related]
19. Aurora-A inhibitor synergistically enhances the inhibitory effect of anlotinib on hepatocellular carcinoma.
Lin X; Pan F; Abudoureyimu M; Wang T; Hao L; Wang R
Biochem Biophys Res Commun; 2024 Jan; 690():149247. PubMed ID: 38000292
[TBL] [Abstract][Full Text] [Related]
20. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor.
Xie C; Wan X; Quan H; Zheng M; Fu L; Li Y; Lou L
Cancer Sci; 2018 Apr; 109(4):1207-1219. PubMed ID: 29446853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
